Introduction
============

The condensin complex, which is highly conserved from bacteria to humans, is essential for proper chromosome condensation and segregation during mitosis and meiosis. There are 2 condensin complexes in human, condensin I and condensin II. These complexes share 2 common core subunits, SMC2/CAP-E and SMC4/CAP-C, and have 3 unique non-SMC subunits. Condensin I contains CAP-D2, CAP-H, and CAP-G, while condensin II contains CAP-D3, CAP-H2, and CAP-G2.[@R1]

It has recently been reported that the condensin complex also has a number of functions during interphase, including DNA repair and transcriptional regulation. Human condensin I is required for the recruitment of PARP-1 to single-strand DNA breaks in HeLa and 293T cells.[@R2] In fission yeast, Cnd2 (human CAP-H), which is the non-SMC subunit of condensin, is synthetic lethal with the DNA replication protein RecQ helicase (human WRN, BLM and RecQL proteins) and is required for Cds1 (human CHK2) activation.[@R3] Furthermore, the fission yeast SMC2 homolog Cut14 is required for DNA annealing.[@R4] Human CAP-G2 is involved in the transcriptional regulation of c-kit in erythroid cells via an interaction with an erythroid-lineage-specific bHLH transcription factor.[@R5] In addition, a genome-wide analysis of budding yeast revealed that the chromosomal condensin pattern does not alter during the cell cycle, and that the minimal condensin-binding consensus comprises a B-box element recognized by RNA polymerase III transcription factor.[@R6]

Although a condensin knockout mouse model is currently unavailable,[@R1] knockdown of *Smc2* induces cell death in mouse embryonic stem cells but not in immortalized mouse embryonic fibroblasts.[@R7] These findings suggest that the condensin complex is not essential for viability and may be differentially regulated across tissues or during development.

The MYC family of proteins comprises MYC (c-myc), MYCN, and MYCL. *MYCN* encodes a transcription factor with a β-helix-loop-helix domain that is specifically expressed in neuronal tissues. Multiple target genes are regulated by MYC, including DNA damage response (DDR) genes.[@R8]^-^[@R12] Cancer cells undergo many stresses, including oxidative and replicative stress.[@R13] According to the oncogene-induced DNA damage model of cancer development,[@R14] genomic instability is induced by oncogenes themselves. In fact, MYC induces DNA damage through reactive oxygen species (ROS) production[@R15] and replicative stress.[@R16]

The DDR is a network of signaling pathways involved in DNA damage repair, cell cycle checkpoints, and apoptosis.[@R17] The MRN complex has been implicated in all aspects of DNA double-strand break (DSB) processing, including initial detection, triggering signaling pathways, and facilitating repair. The MRN complex also activates ataxia-telangiectasia mutated (ATM) and related kinases that promote rapid phosphorylation of multiple proteins and of chromatin structure around the break sites. The 2 major DSB repair pathways are homologous recombination and non-homologous end-joining (NHEJ).[@R18] BRCA1 is a versatile protein that links DNA damage sensing and DDR effectors. This protein is directly involved in homologous recombination-mediated repair of DSBs and may also function in other DNA repair pathways, including NHEJ and single-strand annealing.

Inhibiting genes that are synthetic lethal with cancer-associated mutations should exclusively kill cancer cells; therefore, identification of such genes is important for identifying new therapeutic targets.[@R19] One of the most well-characterized therapeutic combinations comprises a *BRCA1* mutation and a poly-ADP-ribose polymerase inhibitor.[@R20]^,^[@R21] To date, multiple specific combinations of genes have been found to show synergistic lethal responses with *MYC* or *MYCN.*[@R22]^-^[@R31]

Neuroblastoma originates from precursor cells of the sympathetic nervous system. *MYCN* oncogene amplification and mutations in the gene encoding anaplastic lymphoma kinase (ALK) are both critically involved in the development of a high-risk clinical phenotype and poor survival probabilities.[@R32]^-^[@R36] There are several animal models of neuroblastoma, including *MYCN* and mutated *ALK* transgenic mice.[@R37] *MYCN* transgenic (Tg) mice, in which MYCN expression is targeted to the sympathetic neuron lineage by rat tyrosine hydroxylase,[@R38] serve as a model of neuroblastoma. These mice develop aggressive neuroblastomas and tumorigenesis, positively correlated with the *MYCN* transgene dosage or the development of additional genetic mutations.[@R39]

Here, we show that SMC2 regulates several DDR genes in cooperation with MYCN, and that knockdown of *SMC2* has a synergistic lethal effect with *MYCN* amplification. SMC2 controls several DDR genes simultaneously; therefore, it may be an effective molecular target for the treatment of *MYCN*-amplified cancers. In addition, we show that patients bearing *MYCN*-amplified tumors tend to benefit from low *SMC2* expression. The results presented here suggest that SMC2 (or the condensin complex) is a molecular target of *MYCN*-amplified cancers.

Results
=======

*Smc2* expression in neuroblastoma model mice and human neuroblastoma cell lines
--------------------------------------------------------------------------------

To gain insights into the molecular pathways governing neuroblastoma development, the expression profiles of superior mesenteric ganglia of 2-wk-old wild-type (wt) mice, precancerous lesions of 2-wk-old homozygote *MYCN* Tg mice, and terminal tumors of 6-wk-old homozygote *MYCN* Tg mice were examined (GSE43419). The expression levels of 79 genes were higher in precancerous lesions and tumors of *MYCN* Tg mice than in ganglia of wt mice. Among these genes, *Smc2* was selected and characterized further. The level of *Smc2* expression gradually increased as the severity of the disease progressed ([Fig. 1A](#F1){ref-type="fig"}). To confirm this finding, semi-quantitative and quantitative RT-PCR (RT-qPCR) analyses of precancerous lesions of 2-wk-old *MYCN* hemizygous mice were performed ([Fig. 1B](#F1){ref-type="fig"}); these lesions are reportedly similar to human *MYCN*-amplified neuroblastoma.[@R39] Consistent with the microarray data, mouse *Smc2* was highly expressed in the precancerous lesion samples ([Fig. 1B](#F1){ref-type="fig"}).

![**Figure 1.***Smc2* expression in neuroblastoma model mice and *SMC2* expression in human neuroblastoma cell lines. (**A**) Results of a microarray analysis of the relative expression levels of *Smc2* in ganglia of wt mice (lanes 1 and 2), and precancerous (lanes 3 and 4) and tumor lesions (lanes 5 and 6) of homozygous *MYCN* Tg mice. (**B**) Semi-quantitative (left) and quantitative (right) RT-PCR analyses of *Smc2* and *Gapdh* (control) expression levels in 3 precancerous lesion samples from hemizygous *MYCN* Tg mice (hemi) and ganglia of wt mouse. (**C**) Semi-quantitative (left) and quantitative (right) RT-PCR analyses of human *SMC2* expression levels in various human neuroblastoma cell lines. SH-SY5Y, SK-N-AS, and SH-EP cells have a single copy of *MYCN,* and IMR32 and SK-N-BE(2) have amplified *MYCN*. The expression levels of *Smc2* and *SMC2* detected by RT-qPCR were normalized to those of *Gapdh* and *GAPDH* respectively.](cc-13-1115-g1){#F1}

The expression of *SMC2* was then examined in human neuroblastoma cell lines. Human *SMC2* expression was higher in *MYCN*-amplified cell lines (IMR32 and SK-N-BE\[2\]) than in *MYCN* single copy cell lines (SH-SY5Y, SK-N-AS and SH-EP) ([Fig. 1C](#F1){ref-type="fig"}). These results indicate that *SMC2* expression is elevated in *MYCN* Tg mice and *MYCN*-amplified human neuroblastoma cells and is correlated with MYCN expression.

Overexpression of MYCN induces SMC2 expression in human neuroblastoma cells
---------------------------------------------------------------------------

To determine whether overexpression of MYCN induces SMC2 expression, a CMV-driven *MYCN* plasmid or a CMV-Venus plasmid (as a control) were introduced into SH-EP *MYCN* single copy cells using a lentivirus. After live cell sorting, RT-PCR and immunoblotting analyses were performed. The levels of SMC2 mRNA and protein were higher in SH-EP cells constitutively expressing MYCN than in control cells ([Fig. 2A and B](#F2){ref-type="fig"}).

![**Figure 2.** Overexpression of MYCN induces *SMC2* expression in human neuroblastoma cells. (**A and B**) A CMV-driven plasmid containing *MYCN* was introduced into the SH-EP *MYCN* single copy cell line. After live cell sorting, the levels of human SMC2 mRNA and protein were measured by semi-quantitative (**A**, left) and quantitative (**A**, right) RT-PCR, as well as by immunoblotting (**B**). The arrowhead in (**B**) indicates a non-specific band. The expression levels of *SMC2* detected by RT-qPCR were normalized to those of *GAPDH*. (**C**) Schematic representation of the E-boxes identified in the human *SMC2* gene. The light gray boxes indicate the 5′ and 3′ UTRs; the dark gray boxes indicate the exons; and the black circles represent putative E-boxes (MYCN-binding sites). The sequences of the E-boxes are shown. (**D**) ChIP followed by qPCR analysis of the E-boxes in the *SMC2* gene was performed using control IgG or an anti-MYCN antibody in SH-EP cells expressing Venus (control) or MYCN. The 5-kb sequence upstream of the *SMC2* gene was examined as a negative control. The data show the percentage of the target DNA precipitated with the control IgG or MYCN antibody and are represented as the mean ± SE of at least n = 3 independent experiments.](cc-13-1115-g2){#F2}

MYC binds to a canonical consensus DNA sequence (CACGTG) named the E-box. MYC also binds to several other non-canonical DNA motifs in vitro, including CATGTG, CATGCG, CACGCG, CACGAG, and CAACGTG.[@R40] Three canonical E-boxes (E-box1, E-box2, and E-box3) were detected within the introns of *SMC2* ([Fig. 2C](#F2){ref-type="fig"}). A chromatin immunoprecipitation (ChIP) assay was used to examine whether MYCN is able to bind to the identified E-boxes ([Fig. 2D](#F2){ref-type="fig"}). When MYCN was overexpressed, the amount of MYCN that bound to E-box2 increased ([Fig. 2D](#F2){ref-type="fig"}). In the control cells, the amount of MYCN bound to E-box2 was also higher than the amount of IgG antibody bound to E-box2 ([Fig. 2D](#F2){ref-type="fig"}); however, this difference is likely due to non-specific binding, because the amount of MYCN bound to the 5-kb upstream region also increased ([Fig. 2D](#F2){ref-type="fig"}). These results indicate that MYCN regulates SMC2 expression by binding to its E-box2 motif.

Knockdown of *SMC2* induces DNA damage and apoptosis
----------------------------------------------------

A short hairpin RNA (shRNA) targeting *SMC2* inhibited proliferation of MYCN-overexpressing SH-EP cells but not of *MYCN* single copy control SH-EP cells ([Fig. 3A](#F3A-C){ref-type="fig"}). By contrast, the proliferation of MYCN-overexpressing SH-EP cells and control SH-EP cells infected with a non-target shRNA was similar ([Fig. 3A](#F3A-C){ref-type="fig"}), indicating that overexpression MYCN and a reduction in *SMC2* expression has a synergistic lethal response. The knockdown efficiency of each cell is shown in [Figure 3B](#F3A-C){ref-type="fig"}.

![**Figure 3A--C.** Knockdown of *SMC2* induces DNA damage and apoptosis. (**A**) Growth of MYCN-overexpressed SH-EP cells and control SH-EP cells infected with non-target shRNA or *SMC2*-specific shRNAs. Counting started 3 d after infection. On each day, 3 plates were counted and averaged. Data are shown as a ratio of the number of cells at 3 d after transfection and are represented as the mean ± SD of n = 3 independent repeats. (**B**) *SMC2* knockdown efficiency of (**A**). (**C**) TUNEL staining of apoptotic IMR32 cells at 6 d after infection (upper panel) and quantification of apoptotic IMR32 cells at the indicated time-points (lower panel). On each day, 3 plates were counted and averaged. (**D**) Immunofluorescence of γ-H2AX and DAPI staining of IMR32 (*MYCN*-amplified), SK-N-BE(2) (*MYCN*-amplified), SK-N-AS (*MYCN*-single copy), and SH-EP (*MYCN*-single copy) cells infected with non-target or *SMC2*-specific shRNA. Images were captured 3 d after infection. (**E**) Quantification of the γ-H2AX-positive cells shown in (**D**). Data are represented as the mean ± SD of n = 3 independent repeats. Their homoscedasticities were checked by f test. Statistical significance was evaluated with a 2-tailed, unpaired *t* test. (**F**) The percentage viability of SH-EP or MYCN overexpressed SH-EP cells infected with non-target or *SMC2*-specific shRNA and treated with cisplatin (left) or campthotecin (right). Data are represented as the mean ± SE of n = 3 independent experiments. Their homoscedasticities were checked by *f* test. Statistical significance was evaluated with a 2-tailed, unpaired *t* test.](cc-13-1115-g3A-C){#F3A-C}

Next, a TUNEL assay was used to determine whether knockdown of *SMC2* and amplification of *MYCN* causes apoptosis. Very few FITC-positive cells were detected in non-infected or non-target shRNA-infected IMR32 cells, but almost all cells infected with *SMC2*-specific shRNA were FITC-positive ([Fig. 3C](#F3A-C){ref-type="fig"}). Most of the *SMC2*-knockdown IMR32 cells were TUNEL-positive at 6 d after virus infection. DNA damage induces apoptosis;[@R41] therefore, the level of DNA damage in these cells was also examined. Histone H2A phosphorylation at a serine residue (γ-H2AX) is a sensitive marker of DSBs.[@R42] The number of γ-H2AX-positive cells was markedly higher in *SMC2*-knockdown IMR32 and SK-N-BE(2) cells than in IMR32 and SK-N-BE(2) cells infected with a non-specific shRNA ([Fig. 3D and E](#F3D){ref-type="fig"}); however, the number of γ-H2AX-positive cells was not increased by knockdown of *SMC2* in the SK-N-AS and SH-EP cell lines. Most of the *SMC2*-knockdown IMR32 cells, and approximately 40% of the non-target shRNA-infected IMR32 cells, displayed γ-H2AX foci. The mechanism that induced DNA damage in the non-target lentivirus-infected *MYCN*-amplified cells is unknown. Despite this outcome, the results suggest that knockdown of *SMC2* induces additional DNA damage in *MYCN*-amplified cells.

![**Figure 3D.** See [Figure 3A--C](#F3A-C){ref-type="fig"}legend.](cc-13-1115-g3D){#F3D}

The induction of ROS production or replication stress by MYC causes DNA damage.[@R15]^,^[@R16] We hypothesized that overexpression of MYCN also induces DNA damage, most of which is repaired in the normal condition, thereby allowing *MYCN*-amplified cells to survive. However, once SMC2 expression is reduced, cells are unable to repair the DNA damage, resulting in subsequent cell death. If these hypotheses are correct, *SMC2*-knockdown cells would be expected to be sensitive to DNA damage even in *MYCN* single copy neuroblastoma cell lines. This hypothesis was tested by treating SH-EP cells, which contain a single copy of *MYCN*, with cisplatin and camptothecin to cause DNA damage. Cisplatin mainly causes intrastrand cross-linking,[@R43] whereas camptothecin, a topoisomerase I inhibitor, causes replication-dependent DSBs.[@R44] Treatment of *SMC2*-knockdown SH-EP cells with cisplatin or camptothecin decreased cell viability ([Fig. 3F](#F3E-F){ref-type="fig"}, upper panels), and treatment of *SMC2*-knockdown MYCN-overexpressed SH-EP cells with cisplation or camptothecin was more sensitive ([Fig. 3F](#F3E-F){ref-type="fig"}, lower panels). These results suggest that MYCN-induced DNA damage is required for the synergistic lethal response with *SMC2* knockdown.

![**Figure 3E and F.** See [Figure 3A--C](#F3A-C){ref-type="fig"}legend.](cc-13-1115-g3E-F){#F3E-F}

SMC2 regulates the expression of DDR genes
------------------------------------------

We next investigated how SMC2 is involved in DNA damage repair. [Table 1](#T1){ref-type="table"} shows mini-ontology data of 3 cohorts, which are available at the R2 microarray analysis and visualization platform (<http://r2.amc.nl>). The first cohort consisted of 88 neuroblastoma patients from the Academic Medical Center in Amsterdam,[@R45] the second cohort consisted of 101 neuroblastoma patients from the Children's Hospital of Philadelphia,[@R46] and the third cohort consisted of 30 neuroblastoma patients from the Leeds and Newcastle NHS Trusts.[@R47]

###### **Table 1.** Mini-ontology of genes correlated with SMC2 expression from published human neuroblastoma expression array data sets (GSE16476, GSE3960, GSE13136) created using the R2 bioinformatic platform (<http://r2.amc.nl>)

![](cc-13-1115-t1)

DDR genes are involved in DNA repair. DDR gene expression increased in parallel with *SMC2* expression ([Table 1](#T1){ref-type="table"}), suggesting a relationship between *SMC2* expression and DDR gene expression. Some DDR genes, including *BRCA1*, *MRE11*, *NBS1*, *RAD50*, and *ATM*, are transcriptionally regulated by MYC.[@R8]^-^[@R12] To determine whether SMC2 is involved in controlling the transcription of DDR genes, qPCR analyses were used to measure the expression levels of some DDR genes regulated by MYC when *SMC2* was knocked down in single copy or in *MYCN*-amplified neuroblastoma cell lines. In IMR32 cells, knockdown of *SMC2* did not affect *β-ACTIN* transcription, but the levels of *BRCA1*, *MRE11*, *NBS1*, *RAD50*, and *ATM* mRNAs decreased ([Fig. 4A](#F4A-B){ref-type="fig"}, left panel). By contrast, knockdown of *SMC2* in SK-N-AS cells had a smaller effect on the expression levels of these genes ([Fig. 4A](#F4A-B){ref-type="fig"}, right panel). Similar results were obtained when experiments were performed with MYCN-overexpressed SH-EP cells and control SH-EP cells ([Fig. 4B](#F4A-B){ref-type="fig"}). These results suggest that SMC2 regulates DDR gene expression in cooperation with MYCN.

![**Figure 4A and B.** SMC2 interacts with MYCN and transcriptionally regulates DDR genes. (**A**) RT-qPCR analysis of the relative expression levels of DDR genes in IMR32 cells (*MYCN*-amplified, top-left panel) and SK-N-AS cells (*MYCN* single copy, top-right panel) infected with non-targeting or *SMC2*-specific shRNA. Expression levels in *SMC2*-specific shRNA-infected cells were normalized to those in the control cells. Bottom panels are shown *SMC2* knockdown efficiency in each cells. (**B**) RT-qPCR analysis of the relative expression levels of DDR genes in MYCN-overexpressed SH-EP cells and control SH-EP cells as similar in (**A**). (**C**) Pull-down assay showing that MYCN interacts with SMC2 and SMC4. CMV-driven MYCN, along with CMV-driven Halo-control, Halo-SMC2 or Halo-SMC4 and Halo-MYCN proteins were expressed in 293T cells. A pull-down assay was performed using a Halo-tag. The proteins were detected with the indicated antibodies. WCE (TMR), TMR Direct ligand stained Halo-tag proteins in whole cell extract. (**D**) SMC2 and MYCN bind to the E-box motif in the *NBS1* gene. The left panel shows the results of a ChIP assay of the E-box in the *NBS1* gene performed using an anti-MYCN antibody in cells expressing Venus (control) or MYCN. The right panel shows the results of a ChIP assay of the E-box in the *NBS1* gene performed using an anti-SMC2 antibody in *MYCN*-amplified IMR32 cells. A region situated 14.5 kb upstream of the E-box was used as a negative control. Data show the percentages of the target DNA precipitated with the antibodies and are represented as the mean ± SE of at least n = 3 independent qPCR experiments. (**E**) The protein level of SMC4 and CAP-D2 when SMC2 is knockdown in MYCN expressing SH-EP (*MYCN* single copy) cells and control Venus expressing SH-EP cells. β-ACTIN is used as loading control.](cc-13-1115-g4A-B){#F4A-B}

MYCN interacts with SMC2 and SMC4
---------------------------------

The possibility of an interaction between SMC2 and MYCN was investigated using a pull-down assay. The results indicated that SMC2, SMC4, and MYCN all interacted with each other ([Fig. 4C](#F4C-E){ref-type="fig"}). Choi and colleagues reported that MYCN associates with SMC4 and SMC2 in FLAG-tagged MYCN-expressing HeLa cells,[@R48] suggesting that this interaction occurs in multiple cell types.

![**Figure 4C--E.** See [Figure 4A and B](#F4A-B){ref-type="fig"}legend.](cc-13-1115-g4C-E){#F4C-E}

The MYC binding site in the *NBS1* gene is the E-box within intron 1.[@R11] To test whether MYCN also binds to this motif, a ChIP analysis was performed using an anti-MYCN antibody. MYCN bound to the E-box motif in the *NBS1* gene ([Fig. 4D](#F4C-E){ref-type="fig"}, left panel). SMC2 bound to the same motif ([Fig. 4D](#F4C-E){ref-type="fig"}, right panel). These results suggest that SMC2 regulates *NBS1* transcription in cooperation with MYCN.

In addition, we found that the protein level of condensin subunit decreased when *SMC2* knockdown ([Fig. 4E](#F4C-E){ref-type="fig"}). This suggests that condensin complex becomes unstable when SMC2 is lost.

Genome-wide analysis of genes regulated by SMC2
-----------------------------------------------

To identify the genes regulated by SMC2, RNA-seq of *SMC2*-knockdown SH-EP cells constitutively expressing MYCN or Venus as a control was performed (SRA081723). A remarkable number of the genes that were induced or repressed in these cells were related to the DDR, DNA repair, or the cell cycle ([Table 2](#T2){ref-type="table"}; [Table S1](#SUP1){ref-type="supplementary-material"}). The results indicated that knockdown of *SMC2* had a larger effect on *ATM* and *RAD50* transcription in SH-EP cells overexpressing MYCN than in the control cells, which agrees with the results of the RT-qPCR analyses shown in [Figure 4A](#F4A-B){ref-type="fig"}. These results suggest that SMC2 effects the expression of a number of genes involved in DNA repair, the DDR, and the cell cycle.

###### **Table 2.** List of induced or repressed GO categolies belonging to DDR, DNA repair, and cell cycle-related classes in *SMC2*-knockdown Venus- or MYCN-expressing SH-EP cells. Non-target shRNA-infected cells were used as a control

  Gene ontology classes enriched in *SMC2*-knockdown Venus-expressing SH-EP cells                                                     
  ------------------------------------------------------------------------------------ ------------------------ --------------------- -----------
  GO term                                                                              Total No. genes in set   No. genes regulated   *P* value
  cell cycle                                                                           828                      225                   2.55E-12
  cell cycle process                                                                   647                      185                   5.77E-12
  cell cycle phase                                                                     548                      158                   2.52E-10
  mitotic cell cycle                                                                   470                      139                   5.97E-10
  DNA metabolic process                                                                594                      157                   1.58E-07
  regulation of cell cycle                                                             526                      139                   2.00E-06
  M phase                                                                              344                      97                    1.95E-05
  chromosome                                                                           471                      124                   1.72E-05
  interphase of mitotic cell cycle                                                     257                      76                    7.92E-05
  M phase of mitotic cell cycle                                                        246                      73                    1.19E-04
  interphase                                                                           261                      76                    1.37E-04
  G1/S transition of mitotic cell cycle                                                126                      45                    1.21E-04
  mitosis                                                                              239                      71                    1.44E-04
  chromosome, centromeric region                                                       124                      44                    1.72E-04
  chromosome segregation                                                               98                       37                    2.82E-04
  cell division                                                                        295                      82                    3.30E-04
  condensed chromosome, centromeric region                                             69                       29                    3.80E-04
  chromosome organization                                                              518                      125                   0.001
  mitotic prometaphase                                                                 73                       29                    0.001
  regulation of cell cycle process                                                     292                      78                    0.003
  condensed chromosome                                                                 124                      41                    0.003
  condensed chromosome kinetochore                                                     64                       25                    0.008
  DNA replication                                                                      147                      45                    0.008
  response to DNA damage stimulus                                                      427                      103                   0.009
  DNA conformation change                                                              159                      47                    0.013
  chromatin                                                                            206                      56                    0.028
  negative regulation of cell cycle                                                    194                      53                    0.037
  cell cycle checkpoint                                                                180                      50                    0.037
  DNA repair                                                                           287                      72                    0.041
  kinetochore                                                                          75                       26                    0.047
  chromatin remodeling                                                                 67                       24                    0.049
  **Gene ontology classes enriched in *SMC2*-knockdown MYCN-expressing SH-EP cells**                                                  
  GO term                                                                              Total No. genes in set   No. genes regulated   *P* value
  gene expression                                                                      1680                     581                   3.86E-15
  response to DNA damage stimulus                                                      427                      179                   1.29E-10
  DNA metabolic process                                                                594                      223                   1.36E-10
  cell cycle process                                                                   647                      244                   4.60E-09
  mitotic cell cycle                                                                   470                      188                   4.64E-09
  cell cycle                                                                           828                      299                   5.90E-09
  chromatin modification                                                               328                      139                   2.72E-08
  DNA repair                                                                           287                      124                   7.03E-08
  covalent chromatin modification                                                      194                      90                    3.67E-07
  histone modification                                                                 192                      89                    4.78E-07
  cell cycle phase                                                                     548                      204                   8.24E-07
  regulation of gene expression                                                        2625                     796                   1.02E-06
  chromosome organization                                                              518                      194                   1.18E-06
  chromatin organization                                                               396                      154                   3.28E-06
  transcription factor binding                                                         284                      116                   1.18E-05
  regulation of cell cycle                                                             526                      191                   2.23E-05
  cell division                                                                        295                      118                   3.28E-05
  mitosis                                                                              239                      98                    1.05E-04
  chromosome                                                                           471                      171                   1.05E-04
  M phase of mitotic cell cycle                                                        246                      100                   1.25E-04
  chromosome, centromeric region                                                       124                      58                    2.26E-04
  regulation of transcription, DNA-dependent                                           2324                     692                   3.00E-04
  transcription cofactor activity                                                      345                      130                   3.10E-04
  protein binding transcription factor activity                                        352                      132                   3.42E-04
  transcription factor binding transcription factor activity                           349                      131                   3.52E-04
  condensed chromosome, centromeric region                                             69                       37                    4.79E-04
  interphase of mitotic cell cycle                                                     257                      101                   6.15E-04
  interphase                                                                           261                      102                   7.27E-04
  M phase                                                                              344                      127                   0.001
  regulation of gene expression, epigenetic                                            96                       46                    0.001
  chromatin remodeling                                                                 67                       35                    0.002
  chromosomal part                                                                     389                      140                   0.002
  negative regulation of gene expression                                               580                      197                   0.002
  mitotic prometaphase                                                                 73                       37                    0.002
  DNA-dependent transcription, initiation                                              76                       38                    0.002
  positive regulation of transcription, DNA-dependent                                  664                      220                   0.003
  condensed chromosome kinetochore                                                     64                       33                    0.004
  cell cycle checkpoint                                                                180                      72                    0.008
  posttranscriptional regulation of gene expression                                    243                      92                    0.008
  transcription, DNA-dependent                                                         794                      254                   0.01
  condensed chromosome                                                                 124                      53                    0.011
  regulation of transcription from RNA polymerase II promoter                          792                      253                   0.011
  positive regulation of gene expression                                               712                      230                   0.011
  chromosome segregation                                                               98                       44                    0.012
  transcription initiation from RNA polymerase II promoter                             51                       27                    0.012
  regulation of cell cycle process                                                     292                      106                   0.013
  transcription coactivator activity                                                   197                      76                    0.016
  regulation of cell cycle arrest                                                      188                      73                    0.017
  spindle                                                                              160                      64                    0.018
  DNA recombination                                                                    130                      54                    0.02
  kinetochore                                                                          75                       35                    0.025
  microtubule organizing center                                                        326                      114                   0.035
  negative regulation of transcription, DNA-dependent                                  521                      171                   0.039
  protein serine/threonine kinase activity                                             364                      125                   0.039
  DNA damage response, signal transduction by p53 class mediator                       71                       33                    0.04
  G~2~/M transition of mitotic cell cycle                                              101                      43                    0.049

Analysis of the potential involvement of SMC2 in neurogenesis
-------------------------------------------------------------

High-risk neuroblastomas may have defects in neuritogenesis genes.[@R49] During zebrafish development, smc2 and smc4 are expressed in some regions of the central nervous system,[@R50] and a mutation in the microcephalin gene disregulates condensin II and causes autosomal recessive primary microcephaly.[@R51] Therefore, we re-analyzed mouse expression array data published in ArrayExpress (E-GEOD-11356, <http://www.ebi.ac.uk/microarray-as/ae/>). *Mycn* was highly expressed in E8.5 (neural tube closure) samples and gradually decreased in E13.5 (dorsal root ganglion) and P90 (adrenal medulla) samples. The expression pattern of *Smc2* was similar to that of *Mycn* ([Fig. S1](#SUP1){ref-type="supplementary-material"}). These data suggest that, along with MYCN, SMC2 (or the condensin complex) may have a role in sympathetic neurogenesis.

Clinical data
-------------

We hypothesized that patients bearing *MYCN*-amplified tumors would benefit from low SMC2 expression. Therefore, we investigated whether *SMC2* expression correlated with patient prognosis in a previous cohort used by Wang et al.[@R46] In *MYCN*-amplified patients, low levels of *SMC2* were associated with good prognosis (overall survival, *P* = 0.051; event-free survival, *P* = 0.053) ([Fig. 5A](#F5){ref-type="fig"}). These results indicate that low *SMC2* expression in *MYCN*-amplified patients tends to correlate with good prognosis.

![**Figure 5.** Clinical data showing the relationship between *SMC2* expression and patient prognosis in the Wang cohort.[@R48] (**A**) The effects of *SMC2* expression on the overall survival (OS) and event-free survival (EFS) rates of patients bearing *MYCN*-amplified and non-amplified tumors. Within each of the 2 tumor subsets considered, those with expression levels of *SMC2* greater than the median (blue or green line) were compared with the remainder of the tumors in the subset (red or purple line) using a Kaplan--Meier analysis. (**B**) Expression levels of condensin I- and condensin II-specific subunits and their relationship to *MYCN* amplification or expression. The data were obtained from a published data set (GSE3960). The red line indicates low MYCN expression or no *MYCN* amplification, and the blue line indicates high MYCN expression or *MYCN* amplification.](cc-13-1115-g5){#F5}

The expression levels of other condensin I and II subunits were higher in precancerous and tumor lesions from *MYCN* Tg mice than in wt mouse ganglion samples; however, the difference was less pronounced than that observed for *Smc2* ([Fig. S2](#SUP1){ref-type="supplementary-material"}). [Table S2](#SUP1){ref-type="supplementary-material"} shows mini-ontology data of three cohorts available at the R2 bioinformatic platform (<http://r2.amc.nl>). The expression levels of most of the condensin I and II subunits correlated with DDR gene expression. We also examined the expression levels of the condensin subunits in the Wang cohort.[@R46] Expression of the condensin I-specific subunits was related to the level of *MYCN* amplification or expression, whereas the expression of condensin II-specific subunits was not ([Fig. 5B](#F5){ref-type="fig"}). [Figure S3](#SUP1){ref-type="supplementary-material"} shows the relationship among MYCN expression, condensin subunit expression, and prognosis of 101 neuroblastoma patients included in the Wang cohort.[@R46] We separated the samples into 2 groups, namely MYCN high expression and MYCN low expression. If patients bearing MYCN-high tumors benefit from low condensin subunit expression, only the subunit-high group of MYCN-high patients would show poor prognosis. That means only MYCN-high group would show the significant difference (*P* \< 0.05). [Figure S3](#SUP1){ref-type="supplementary-material"} shows that patients expressing high levels of MYCN and condensin I subunit (CAP-D2) or SMC4 had poor prognosis, although prognosis of those expressing condensin I subunit (CAP-H) was not always related to MYCN expression. However, prognosis of patients expressing condensin II subunit was not related to MYCN expression. These results suggest that SMC2 may function as a condensin complex (probably as condensin I), rather than alone, in this phenotype.

Discussion
==========

This study demonstrates that (1) *SMC2* is regulated by MYCN; (2) SMC2, in cooperation with MYCN, regulates DDR genes; and (3) downregulation of *SMC2* and concomitant *MYCN* amplification induces DNA damage and has a synergistic lethal effect, resulting in apoptosis of human neuroblastoma cells. This study also demonstrates that patients bearing *MYCN*-amplified tumors tend to benefit from low SMC2 expression. A model summarizing these findings is shown in [Figure 6](#F6){ref-type="fig"}. In *MYCN*-amplified cells, MYCN induces DNA damage, most likely via the production of ROS and replicative stress. On the other hand, since SMC2 is overexpressed in these cells, the DDR may also be highly activated. As a consequence, cells are viable, but some mutations would still remain ([Fig. 6A](#F6){ref-type="fig"}, left). In this situation, knockdown of *SMC2* would impair the DDR, resulting in cell death ([Fig. 6A](#F6){ref-type="fig"}, right). By contrast, in *MYCN* single copy cells, the extent of DNA damage is lower, and knockdown of *SMC2* does not affect cell viability ([Fig. 6B](#F6){ref-type="fig"}).

![**Figure 6.** Schematic model showing the synergistic effects of SMC2 and MYCN in *MYCN*-amplified (**A**) and *MYCN* single copy (**B**) cells. This model is based on the proposed transcriptional regulation by MYCN and SMC2 (**C**).](cc-13-1115-g6){#F6}

Several reports have suggested that the condensin complex is required for the recruitment of DNA repair proteins to damage sites.[@R2]^,^[@R52]^,^[@R53] In this study, we found that SMC2 interacts with MYCN and is involved in transcriptional regulation of DDR genes, and that *SMC2* expression is regulated by MYCN as well as by Wnt[@R54] ([Fig. 6C](#F6){ref-type="fig"}). There are several advantages of using SMC2 as a molecular target for the treatment of *MYCN*-amplified neuroblastoma. First, knockdown of *SMC2* has similar effects to knockdown of several DDR genes. Second, if MYC functions similarly to MYCN, inhibition of SMC2 would be expected to have growth-inhibitory activity in MYC-overexpressed/amplified cancers. If so, SMC2 knockdown is a powerful tool for both MYCN- and MYC-overexpressed/amplified cancers.

There are still some unanswered questions. First, other than MYCN, which other transcription factors interact with SMC2 or the condensin complex? CAP-G associates with bHLH transcription factors in erythroid cells;[@R5] therefore, SMC2 (or the condensin complex) may co-operate with various transcription factors in different tissues or developmental stages. The second question relates to the mechanism by which SMC2 is involved in transcriptional regulation. SMC2 associates with MYCN, but its specific role in the MYCN complex remains unknown. SMC2 may act as a co-factor or alter the chromosomal conformation. Third, what is the functional difference between MYC and MYCN? *MYCN*-amplified neuroblastoma cells express low levels of MYC, while *MYCN* single copy neuroblastoma cells express higher levels.[@R24] As described above, knockdown of *SMC2* had a synergistic lethal effect with amplification or overexpression of *MYCN,* but this effect was not seen in *MYCN* single copy cells. This result implies that knockdown of *SMC2* is synergistic lethal with *MYCN* but not with *MYC*. It might also suggest that the gene set that shows a synergistic lethal effect with *MYCN* is different from that associated with *MYC*amplification or overexpression. CDK2,[@R26] Aurora A,[@R27] and CHK1[@R22] kinases show specific synergistic lethal responses with *MYCN*, but not with *MYC* in *MYCN* single copy cells. However, another report demonstrated that MYC and MYCN are functionally redundant to some extent,[@R55] and the gene(s) that are synthetic lethal with *MYC* overexpression in human foreskin fibroblasts are also synthetic lethal with *MYCN*, but not with *MYC* in *MYCN* single copy cells.[@R24]^,^[@R56] Further studies are required to elucidate the relationship between MYC and MYCN.

Materials and Methods
=====================

Mice
----

*MYCN* Tg mice[@R38] were maintained in the animal facility at Nagoya University Graduate School of Medicine where they were housed in a controlled environment and provided with standard nourishment and water. Normal ganglia and precancerous and tumor tissues from wt, hemizygous, and homozygous *MYCN* Tg mice were dissected and minced, and then total RNA was extracted. This study was approved by the Animal Care and Use Committee of Nagoya University Graduate School of Medicine, Nagoya, Japan.

Gene expression profiling
-------------------------

Total RNA was isolated using ISOGEN reagent (Nippon Gene), according to the manufacturer\'s instructions. Samples were analyzed with a GeneChip Mouse Genome 430 2.0 array (Affymetrix). Preparation of target cDNA from total RNA, hybridization to the microarray, washing, staining with an antibody amplification procedure, and scanning were all performed according to the manufacturer\'s instructions. The expression value (Signal) of each probe set was calculated using GeneChip Operating Software (GCOS) version 1.3 (Affymetrix). The data described in this manuscript have been deposited in the Gene Expression Omnibus database of NCBI (<http://www.ncbi.nlm.nih.gov/geo>) under the accession number GSE43419.

Cell lines, virus infection, and transfection
---------------------------------------------

IMR32 cells were obtained from JCRB (JCRB9050); 293T (RCB2202) cells were obtained from the RIKEN Cell Bank; SH-SY5Y, SK-N-AS, and SK-N-BE(2) cells were purchased from ATCC (CRL-2266, CRL-2137, and CRL-2271); SH-EP cells were a gift from Dr Schwab (Division of Tumor Genetics, German Cancer Research Center), and NB39 cells were a gift from Dr Chiba (Fukushima Medical University).

IMR32 cells were grown in minimum essential medium (Sigma) supplemented with 10% fetal bovine serum (HyClone, Thermo Scientific) and 1% non-essential amino acids (GIBCO-Life Technologies). SK-N-AS cells were grown in Dulbecco modified Eagle medium (MP Biomedicals, LLC) supplemented with 10% fetal bovine serum and 1% non-essential amino acids. SK-N-BE(2) and SH-SY5Y cells were grown in a 1:1 ratio of minimum essential medium and Ham-F12 (GIBCO-Life Technologies) supplemented with 10% fetal bovine serum (HyClone, Thermo scientific), 1% sodium pyruvate (Sigma), 1% GlutaMAX (GIBCO-Life Technologies), and 1% non-essential amino acids. 293T cells were grown in Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum. SH-EP cells were grown in RPMI1640 (Sigma) supplemented with 10% fetal bovine serum.

Replication-defective, self-inactivating lentiviral vectors were used.[@R57]^,^[@R58] HEK293T cells were co-transfected with shRNA plasmids in addition to psPAX2 (Addgene) and pMD2.G (Addgene) or cDNA expression plasmids . Neuroblastoma cell lines were infected in the presence of 15 μg/ml polybrene (Sigma). 293T cells were transfected with various plasmids using FuGENE HD reagent (Promega), according to the manufacturer's instructions.

Plasmids
--------

Constructs were generated by PCR using specific primers and a gateway cassette containing a full-length clone of human MYCN. This fragment was initially cloned into pDONR221 (Invitrogen) and then into the CSII-CMV-RfA-IRES-Venus plasmid. The successful introduction of this fragment into each construct was confirmed by DNA sequencing. The CSII-CMV-RfA-IRES-Venus plasmid and the CSII-CMV-Venus control plasmid were kindly provided by H Miyoshi (RIKEN). Commercially available non-targeting (Sigma) and SMC2-specific shRNA vectors (TRCN0000062540, TRCN0000062542, TRCN0000062538; Thermo Scientific Open Biosystems) were used. The shRNA sequences are listed in [Table S3](#SUP1){ref-type="supplementary-material"}.

For pull-down and ChIP assays, the following Halo-tag Flexi ORF clones (Promega) were used: Halo-control (G6591), Halo-SMC2 (pFN21AE9255), Halo-SMC4 (pFN21AB7320), and Halo-MYCN (pFN21AB8396). A list of the plasmids used in the study is provided in [Table S4](#SUP1){ref-type="supplementary-material"}. Further details are available upon request.

DNA damaging agents
-------------------

Cells were treated with cisplatin (NIPPON-KAYAKU) or camptothecin (Sigma). Treatments were performed at 37 °C for overnight and at 14 μM (for SH-EP cells) or 7 μM (for MYCN-overexpressed SH-EP cells) cisplatin and 0.05 μg/ml camptothecin.

Primers
-------

The sequences of the primers used in the study are listed in [Table S5](#SUP1){ref-type="supplementary-material"}.

Isolation of RNA, RT-PCR, and qPCR
----------------------------------

Total RNA was isolated from cells or tissues using ISOGEN II reagent (Nippongene, Japan). For RT-PCR and RT-qPCR analyses, total RNA (1 μg) was incubated with DNase I (Invitrogen) to eliminate contaminating genomic DNA, and then reverse transcribed with oligo(dT) and random hexamer primers and the ThermoScript RT-PCR system (Invitrogen). Quantitative PCR analyses were performed using an Mx3000p or Mx3005p instrument (Agilent Technologies) and the KAPA SYBR Fast qPCR kit (KAPA Biosystems). The expression levels of mouse *Smc2* and *Gapdh* (control), and human *SMC2*, *MYCN*, *GAPDH* (control), *BRCA1*, *MRE11*, *NBS1*, *RAD50*, *ATM*, and *β-ACTIN* were determined using the ^ΔΔ^CT method.

TUNEL assay
-----------

The TUNEL assay was performed using the APO-DIRECT kit (556381, BD Pharmingen). The manufacturer's protocol for cell fixation and staining was followed and then the APO-DIRECT samples were analyzed using a FACSCanto flow cytometer (BD Pharmingen) and Diva software.

Antibodies
----------

The following antibodies were used: anti-MYCN monoclonal antibodies (OP13, Calbiochem and NB200-109, Novus Biologicals); anti-MYCN monoclonal antibody (B8.4.B) (sc-53993, Santa Cruz); anti-SMC2 rabbit polyclonal antibodies (GTX10411, GeneTex; and ab10412, Abcam); anti-β-ACTIN monoclonal antibody (AC-15) (A5441, Sigma); anti-SMC4 rabbit polyclonal antibody (ab17958, Abcam); anti-CAP-D2 rabbit polyclonal antibody (A300-601A, Bethyl Laboratories); and anti-phospho-histone H2A.X (Ser139) mouse monoclonal antibody (JBW301, Millipore).

Immunofluorescence
------------------

For immunofluorescence, cells were grown on glass coverslips in 4- or 8-well plates. The coverslips were washed twice with phosphate-buffered saline (PBS) and then fixed with 4% paraformaldehyde for 1 h at room temperature. Fixed cells were washed with PBS a further 3 times and permeabilized with PBS containing 1% Triton X-100 for 30 min at room temperature. The cells were incubated with an anti γ-H2AX antibody (1:1000 dilution) for 1 h at room temperature and then with Alexa Fluor 488-conjugated anti-mouse IgG (Molecular Probes) (1:1000 dilution) for 30 min at room temperature. After incubation for 5 min with 0.1 μg/ml 4\'6-diamidino-2-phenylindole, cells were mounted in FluorSave Reagent (Millipore). All images were subsequently processed using MetaMorph and Adobe Photoshop.

Protein preparation and immunoblotting
--------------------------------------

Cells were washed with ice-cold PBS and then lysed with RIPA buffer (50 mM Tris-HCl \[pH 8.0\], 150 mM NaCl, 1% NP-40, 1% deoxycholic acid sodium salt monohydrate, 0.1% sodium dodecyl sulfate, and 1% protease inhibitor cocktail). Cell lysates were centrifuged at 4 °C for 10 min at 22,140 g and then analyzed by 10% PAGE. Proteins were transferred to PVDF membranes, which were then blocked for 1 h with PBS containing 5% non-fat dried milk and 0.05% Tween-20. The membranes were washed, probed with primary antibodies, and then exposed to horseradish peroxidase-conjugated secondary antibodies. Blots were visualized using ECL reagent (GE Healthcare) and autoradiography film.

Pull-down assay
---------------

The HaloTag Mammalian Pull-Down System (Promega) was used according to the manufacturer\'s instructions. CMV-driven MYCN with CMV-driven Halo-control, Halo-SMC2, or Halo-SMC4, and Halo-MYCN proteins were expressed in 293T cells. Cells were harvested 64 h after transfection, according to the manufacturer's protocol. Briefly, HaloTag fusion proteins, along with their interacting proteins, were captured using the HaloLink resin and washed gently. Interacting proteins were eluted from the resin with SDS elution buffer and subjected to SDS-PAGE followed by electroblotting.

ChIP
----

Sub-confluent SH-EP cells expressing Venus or MYCN and IMR32 were cultured in 10-cm dishes and treated with 1% (v/v) formaldehyde for 10 min at room temperature. Cross-linking was stopped by adding glycine to a final concentration of 125 mM. The cells were washed with cold PBS and then harvested. The cells were pelleted, frozen at −70 °C, and then lysed by mechanical disruption. The Halo--ChIP system (Promega) was then used according to the manufacturer's instructions, except that an anti-MYCN antibody and Dynabeads-protein G (Dynal) were used. DNA was purified twice using phenol-CIAA. The purified DNA was PCR-amplified using primers spanning the MYCN-binding site in the *SMC2* and *NBS1* genes. Cells immunoprecipitated with control IgGs were used as a negative control.

RNA-seq analysis
----------------

Cells were harvested 72 h after infection with non-target or *SMC2*-specific lentiviruses. Total RNA was prepared from the cells using the RNeasy mini kit (Qiagen), according to the manufacturer\'s instruction. The TruSeq RNA Sample Preparation Kit v2 (Illumina, Inc) was used to prepare RNA-Seq libraries following the manufacturer's instructions. Libraries were sequenced with the Illumina HiSeq 2500 sequencer for 50-bp single read. The data described in this manuscript have been deposited in the Sequence Read Archive database of NCBI (<http://www.ncbi.nlm.nih.gov/sra>) under the accession number SRA081723.

Analysis of human neuroblastoma tumor profiles
----------------------------------------------

Three clinical neuroblastoma gene expression data sets were used for the analysis. As described by Molenaar et al.[@R49] (accession number: GSE16476, [www.ncbi.nih.gov/geo](http://www.ncbi.nih.gov/geo)), Wang et al.[@R59] (accession number: GSE3960, [www.ncbi.nih.gov/geo](http://www.ncbi.nih.gov/geo)), and Lastowska et al.[@R47] (accession number: GSE13136, [www.ncbi.nih.gov/geo](http://www.ncbi.nih.gov/geo)), the basis of these data sets differs markedly, both with respect to the selection of patient cohorts and to the microarray technologies used. The Molenaar data included 88 patients and microarrays were performed using the Affymetrix Human Genome U133 Plus 2.0 array. The Wang data included 101 cases, and microarrays were performed using the Affymetrix HgU95Av2 array. The Lastowska data included 30 neuroblastomas and microarrays were performed using the Affymetrix Human Genome U133 Plus 2.0 array. For the Molenaar, Wang, and Lastowska studies, the normalized microarray data deposited in the Gene Expression Omnibus database were used. For the Wang data, quality filtration was applied as described previously.[@R46]

In [Figure 5A](#F5){ref-type="fig"}, we analyzed the gene expression and survival data in Wang cohort study.[@R48] We divided the entire sample into four groups: (red) those with non-MYCN amplification and the SMC2 expression levels lower than the median value; (blue) those with non-MYCN amplification and the SMC2 expression levels higher than the median value; (green) those with MYCN amplification and the SMC2 expression levels higher than the median value; (purple) those with MYCN amplification and the SMC2 expression levels lower than the median value. Then, the significance of the difference in survival between red vs. blue and green vs. purple are examined by using Kaplan--Meyer plots and Log-rank test. The top 2 panels are plots with overall survival, whereas the bottom 2 panels are with event-free survival. In [Figure 5B](#F5){ref-type="fig"}, we divided the entire sample of published data set (GSE3960) into those with higher and lower MYCN expressions than the median value. The plotted are the density estimates (density esimate is considered as a smoothed histogram which can be computed by using kernel density estimation algorithm kde in R) of condensin I- and condensin II-specific subunits. The given *P*values dictate the significance of the difference between 2 expression densities (by using *U* test).
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